ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1585

Liver Cyst Infection After Hepatic Transcatheter Arterial Embolization in Patients with Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Oda, Yasuhiro, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Ikuma, Daisuke, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Mizuno, Hiroki, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Sekine, Akinari, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Yamanouchi, Masayuki, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Suwabe, Tatsuya, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Hoshino, Junichi, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Ubara, Yoshifumi, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
Background

Hepatic transcatheter arterial embolization (TAE) is a non-surgical treatment to reduce the volume of enlarged liver in patients with autosomal dominant polycystic kidney disease (ADPKD). The incidence of liver cyst infection after hepatic TAE is not known.

Methods

Patients with ADPKD who underwent hepatic TAE between January 2014 and July 2019 in Toranomon Hospital Kajigaya to reduce the volume of enlarged liver were retrospectively analyzed for their history of liver cyst infection before and after hepatic TAE.

Results

107 patients were included in the study. The mean ± standard deviation (SD) of age and height-adjusted total liver volume was 53.9 ± 9.6 years and 5,048 ± 2,124 mL, respectively. 26 patients (24%) were men, and 36 patients (34%) were on renal replacement therapy. Seven patients (7%) had a history of liver cyst infection before hepatic TAE. During the follow-up period, 16 patients (15%) experienced 20 liver cyst infections in total after hepatic TAE, and only one of them had a history of liver cyst infection before hepatic TAE. The mean ± SD of the follow-up period was 714 ± 601 days, while median [interquartile range] was 467 [225-1,078] days. 10 out of 16 patients were on renal replacement therapy, which were all hemodialysis. Four out of 20 liver cyst infections occurred within three months of hepatic TAE. The incidence rate of liver cyst infection after hepatic TAE was 96 cases per 1,000 person-years.

Conclusion

This is the first report on the incidence of liver cyst infection after hepatic TAE. Although comparison with a control group without hepatic TAE is necessary to evaluate the risk of liver cyst infection caused by hepatic TAE, setting a control group with a similar background is difficult and remains a research question.